Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

Medlab Clinical expanding cannabis-based medicines into Europe

By having a European subsidiary, Medlab can save on drug registration fees.

In Australia, Medlab has proceeded to stage II for its cannabis cancer trial

() has formally incorporated a wholly owned subsidiary MDC Europe Limited to facilitate expansion into Europe.

The subsidiary will be used specifically for current and future dealings regarding NanaBis™ and the proposed drug registration models as per the European Medicines Agency (EMA). 

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

European registration of NanaBis™ progressing

Meetings have been held with EMA on the pathway for registration of NanaBis™.

Continue reading
  3 Hits

Medlab Clinical progresses through trials, overseas registration process

Medlab Clinical () has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.

CEO Sean Hall distinguishes Medlab Clinical () from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.

Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  3 Hits

Medlab Clinical substantial shareholder Farjoy lifts holding through on-market purchases

The Sydney-based investor has demonstrated confidence in the company’s medical research strategy.

Farjoy now holds almost 24 million shares, or 11.53%, of Medlab

() substantial shareholder Farjoy Pty Ltd has increased its holding in the company through a series of on-market purchases.

The Sydney-based investor now holds almost 24 million shares, or 11.53%, of Medlab, up from 10.51%.

Since 17 August 2018, Farjoy has acquired more than 2.123 million shares on-market at prices ranging from 34 cents to 43 cents.

The total value of these acquisitions is almost $840,000.

Continue reading
  3 Hits

Medlab Clinical proceeding to stage II for cannabis cancer trial

The company will now proceed with stage II of the human clinical trial.

Stage I findings showed that NanaBis™ is safe indications confirm it helps with pain reduction

() has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial. 

Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.

Continue reading
  3 Hits

Medlab's Hall: "Time to offer something new" to challenge reliance on opioids

's () Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle.

Hall adds that the company is currently intent on marketing the product in around 18 countries, including the EU, the US, Canada, and Australia.

Hall also says that the firm is currently talking to several pharmaceutical firms, two of which are of "significant note".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  2 Hits

Medlab Clinical receives vital licence to export cannabis

The licence opens up potential international markets for its cannabis-based medicines.

The two cannabis-based medicines are NanaBis™ and NanaBidial™

() has received a Licence to Export Cannabis from Australia’s Office of Drug Control.

The export licence will allow Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the company can now supply legally overseas.

Medlab’s CEO Dr Sean Hall said: “This Licence is a welcome addition to our other approvals, allowing Medlab to research, manufacture, conduct research trials, supply within Australia, and now, pending the right partner, foreign markets.”

WATCH: Medlab's Hall: "Time to offer something new" to challenge reliance on opioids

Medlab has developed two cannabis-based medicines, NanaBis™ and NanaBidial™, which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Continue reading
  3 Hits

Medlab Clinical receives positive early research results for NanoCelle™

NanoCelle™ is a mouth spray delivery system targeting cannabis-based medicines.

Research is being conducted by University of Sydney’s Nano Institute

() has received preliminary results from research underway that is reviewing its patented delivery platform, NanoCelle™.

NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™. 

The research has concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.

The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.

Continue reading
  2 Hits

Medlab Clinical Ltd advances research amid nutraceuticals revenue growth

Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotics.

Medlab’s ahead-of-schedule clinical programs have contributed to its cash burn

() has increased annual revenues by 25% to $5.5 million while increasing its net tangible assets per security by 518% to 10.5 cents.

The results came on the back of a 25% increase in net loss to $4.6 million.

Medlab reported the net loss increase was due to the accelerated costs of its research projects, with some up to 18 months ahead of schedule, and NanaBis costs related to the Federal Government’s Special Access Scheme (SAS).

Cash receipts were up 47% as the company ended June 30 with a $20.3 million cash balance.

Continue reading
  2 Hits

Medlab Clinical researching links between gut microbiome and multiple chronic diseases

() CEO & managing director Dr. Sean Hall tells Proactive Investors, "probably one of the biggest things in medicine to date" is research into the human microbiome and its impact on human health.

Modern research on the field stems from The Human Microbiome Project conducted by the US National Institute of Health starting in 2008, intended to broaden medical understanding of the role of bacteria living in and on humans.

Medlab has taken particular interest in the gut microbiome, and its connection with various chronic diseases. Research into the link with depression is the most advanced, with human patients currently being recruited for Phase IIA clinical trials of NRGBiotic™. The biotech is also researching and developing probiotic applications for the treatment and management of diabetes and chronic kidney disease.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  1 Hits

Medlab Clinical to begin clinical trial of nutraceutical product in oncology patients

Focus of trial on safety and tolerability for oncology patients undergoing chemotherapy.

Trial is for mucositis which affects +40% of chemotherapy patients

() is commencing a safety study for oncology patients undergoing chemotherapy using its patented nutraceutical product, Multibiotic™.

Multibiotic is a multi-species probiotic that helps to support the natural balance of commensal bacteria in the gastrointestinal tract.

It is currently in the market and is used to improve symptoms of medically diagnosed irritable bowel syndrome.

Continue reading
  2 Hits

Medlab Clinical substantial shareholder Farjoy demonstrates confidence in medical research strategy

Sydney-based investor has increased its interest to 10.51% through on-market purchases and placement participation.

Medlab is focused on deliveries therapies for a range of chronic conditions

() substantial shareholder Farjoy Pty Ltd has demonstrated confidence in the company’s medical research and development strategy by lifting its interest to 10.51% from 9.33%.

The Sydney-based investor has made a series of recent on-market purchases and also participated in a Medlab placement.

Farjoy acquired more than 4.1 million shares valued at almost $3.7 million in the placement and has made on-market purchases totalling 800,000 shares valued at more than $357,000.

It now holds more than 21.855 million shares, up from 15 million.

Continue reading
  2 Hits

Medlab Clinical has in place 'the fundamentals to a very successful future'

() CEO & managing director Dr. Sean Hall speaks with Proactive Investors about the biotech's various research and development programs, focused on delivering therapies for a range of chronic conditions.

"Oncology, specifically pain which is our cannabis area, is a main focal point, it's probably one of our most accelerated areas. Second to that, one of our more recent announcements is in the area of depression where we're looking at increasing efficacy in standard depression medications. Outside that, we have advanced areas of influence in diabetes, chronic kidney disease, ageing... From that we get a pharmaceutical division [that] makes actual drugs that go before registration and we commercialise; [and also] we have a Nutraceutical division that is in-market now," explains Hall.

Trials of Medlab’s NRGBiotic™ product for the treatment of depression are entering Phase II, with Hall describing the research as "a couple of years ahead of its time curve."

Meanwhile, Medlab's cannabis-based research arms are progressing well, with the most-advanced NanaBis™ medication in human trials and licensed under the Therapeutic Goods Administration's (TGA) Special Access Scheme.

  3 Hits

Medlab Clinical receives large shipment of cannabis oil for human trials

Medlab has already developed two cannabis-based medicines, NanaBis™ and NanaBidial™.

NanaBis™ will be administered by medicine delivery platform, NanoCelle™

() is set to receive its largest international shipment of cannabis oil to date from Inc. ().

The shipment is part of an agreement between Aphria and Medlab in which Aphria produces and supplies high-yield cannabis extracts for Medlab to be used in human trials.

Trials are testing the management of intractable pain in oncology patients and is the first trial of its kind globally.

For the purposes of the clinical trial, Medlab will receive a specifically designed high-CBD cannabis oil and a high-THC cannabis oil.

Continue reading
  3 Hits

Medlab Clinical begins recruitment for phase IIa clinical trial for depression medicine

The trial is designed to meet the Therapeutic Goods Administration's requirements for expedited drug approval.

Annual cost of mental illness in Australia is $20 billion

() has commenced a recruitment campaign for participants in a clinical trial of a medicine for the treatment of depression.

The trial is being led by Queensland University of Technology (QUT) in Brisbane which is running the recruitment campaign.

Notably, two phase I trials have already shown significant patient improvement on the combination of Medlab’s NRGBiotic™ product with a standard anti-depressant medicine.

READ: Medlab Clinical Ltd initiates phase IIa after positive anti-depression results

The phase IIa study is designed to strengthen those initial findings in a wider group of patients, with the recruitment campaign intended to enrol 150 people diagnosed with depression.

Continue reading
  3 Hits

Medlab Clinical on schedule with medicinal cannabis cancer trial

Medlab has approval to supply NanaBis™ under the TGA's Special Access Scheme.

Earlier this year, the company raised $24 million in a placement

() is on schedule with recruitment for the clinical trial of its cannabis-based cancer medicine, NanaBis™, at Royal North Shore Hospital in Sydney.

The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.

READ: Medlab Clinical begins trial of cannabis-based cancer pain management medicine

The recruitment update coincides with separate positive feedback received from doctors who have been prescribing the medicine.

Feedback from some doctors is that it is proving effective in decreasing reliance on opioids and in its speed of action, aided by delivery through Medlab’s nano-particle spray, NanoCelle™

Continue reading
  3 Hits

Medlab Clinical begins trial of cannabis-based cancer pain management medicine

The trial will test the safety, efficacy and dose tolerance in cancer patients.

Medlab is developing medicines for pain management

Ltd () has commenced the trial of NanaBis™, its cannabis-based medicine for advanced cancer pain at Royal North Shore Hospital (RNSH) in Sydney.

The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.

Medlab managing director Dr Sean Hall said: “This is what we have been working towards.

“It’s a key milestone for the company, we have a validated GMP Australian manufactured product that is being used in a robust and much-needed trial.”

Continue reading
  3 Hits

Medlab Clinical on track for analytical release of Nanabis pain management medicine

Medlab developed the nanoparticle medicine delivery system, Nanocelle.

On validation of the manufactured product, Medlab will be in a position to supply Nanabis

Ltd (), a developer of cannabis based medicines, has made solid progress with its proprietary pain management product, Nanabis.

Nanabis is an Australian produced medicine made to Australian standards in an Australian approved facility and the in house developed Nanocelle, is a unique delivery system. 

The medicine will be supported by trial data, giving prescribers confidence in quality and efficacy.

Medlab is developing therapies for pain management, depression and obesity, and it is already earning revenue from the sale of nutritional products in Australia and the US.

Continue reading
  2 Hits

Medlab Clinical attracts $24 million for cannabis based medicine

NanaBis is a mouth spray and will be clinically tested in advanced stage cancer patients.

New funds are expected to help accelerate commercialisation

Ltd () has successfully completed a placement of shares to institutional and sophisticated investors to raise $24 million at $0.90 per share.

Last year, the company had received approvals to begin human trials of its cannabis based medicine - NanaBis.

NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.

The new funds will help accelerate the commercialisation of NanaBis™. Medlab's NanaBis program is already running 12-18 months ahead of schedule.

Continue reading
  3 Hits

Medlab Clinical wins patent for its unique anti-depression product

350 million people worldwide suffer from depression.

NRGBiotic has demonstrated significant benefits

Ltd () has been granted a 20-year patent covering the Australian market for its probiotic product, NRGBiotic™.

NRGBiotic is a probiotic formula which is indicated to support healthy cellular energy production.

The probiotic species help to support a healthy gut microbial profile and support a healthy immune system.

Interestingly, the current clinical research outcomes for NRGBiotic have provided a novel adjunct option for those with depression.

Continue reading
  3 Hits

Medlab Clinical establishes strategic alliance for nutritional products

The company already has a portfolio of 24 evidence-based nutritional products.

Medlab has developed a nano-particle spray to the inside of the cheek

Ltd () has established a strategic alliance with Heritage Brands, to develop over-the-counter well-being solutions for the pharmacy retail channel.

Heritage Brands is an Australian-owned company, which operates in the health, wellness and beauty markets.

This would be an additional sales channel for Medlab which currently markets its specialised nutritional products to doctors, naturopaths and other relevant practitioners in Asia, New Zealand and Australia.

The company recently received ethics approvals to proceed with two clinical trials for its cannabis based medicines which are administered using NanoCelle™.

Continue reading
  3 Hits